Navigation Links
New Injectable Collagen Filler Offers Natural Results
Date:7/9/2008

N. DALLAS and PLANO, Texas, July 9 /PRNewswire/ -- SKINTASTIC(TM) Medical and Surgical Rejuvenation Center is pleased to announce the arrival of newly FDA-approved EVOLENCE(R) -- the latest injectable collagen filler in the Skintastic arsenal of little-or-no-downtime beauty treatments.

EVOLENCE(R) boasts immediate, predictable visible results, with little swelling. Less bruising and pain were also reported with EVOLENCE(R) in a comparison study against a popular dermal filler.

EVOLENCE(R) differs from other cosmetic filler giants in its unique formulation; EVOLENCE(R) utilizes highly-purified porcine Type I collagen, regarded as a preferred medical grafting substance due to its nearly identical similarity to human collagen. In comparison to one of the popular, hyaluronic acid, sugar-based gel fillers that are gradually absorbed into the body, EVOLENCE(R) is injected deeper into the dermis where it forms a 3D cellular matrix -- replacing the skin's depleted collagen with new collagen (instead of a collagen substitute), for longer-lasting, natural-looking results. Unlike some other animal-based collagen fillers, EVOLENCE(R) requires no skin-test prior to treatment.

All injectable treatments at Skintastic are performed by cosmetic surgeon Jeffrey Adelglass, MD, FACS. According to Dr. Adelglass, "Skintastic is always searching for new aesthetic treatments offering even longer-lasting, consistently-great results for our cosmetic patients -- treatments that are minimally-invasive and take very little time away from a busy schedule." Most of Skintastic's medical spa treatments can be performed in under an hour. Dr. Adelglass adds that while each of the fillers Skintastic employs offers a unique benefit, a key EVOLENCE(R) advantage is that its immediate visible correction should result in high satisfaction in patients seeking real, natural-appearing collagen replacement.

Experience counts. Jeffrey Adelglass, M.D., F.A.C.S. was the first Texas physician to recently achieve simultaneous Diamond pinnacle-level status as a Botox(R) injector and Triple-Platinum status with Medicis, the makers of Restylane(R) and Perlane(R) injectable fillers. Dr. Adelglass is a member of the Star Program -- a group of cosmetic physicians specially-trained to work with EVOLENCE(R), and an exclusive Black Card member of Radiesse(R) physician injectors. He serves on the scientific advisory boards of most, if not all U.S. dermal filler companies, and on the National Education Foundation for Allergan, instructing other cosmetic physicians to safely administer Botox(R) using his well-honed injection techniques. Dr. Adelglass is also an official training instructor for SmartLipo(TM) laser body sculpting, the DOT Fractional skin resurfacing laser, ArteFill(R) and Juvederm(R) dermal fillers. With his level of experience, it's no wonder that many of the representatives of these companies, with all their available options, select Dr. Adelglass as their own cosmetic physician of choice.

The cost of EVOLENCE(R) is expected to be comparable to that of other currently-popular dermal fillers. Call (972) 620-3223 to be added to a waiting list to receive a complimentary EVOLENCE(R) evaluation (and special introductory offer). EVOLENCE(R)-related questions can also be forwarded to skintastic@skintastic.com. Skintastic is located in the Presbyterian Plano Center for Diagnostics and Surgery at 6020 W. Parker, Suite 400 in Plano, Texas.


'/>"/>
SOURCE SKINTASTIC(TM) Medical and Surgical Rejuvenation Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables
2. Dr. Arnold Klein Warns of Dangers With Permanent and Longer Lasting Injectable Fillers
3. Clarity on Cosmetic Injectable Labeling and Use
4. Injectable Antibiotic Protects Against Lyme Disease in Mice
5. Nanomedicine system engineered to enhance therapeutic effects of injectable drugs
6. Galderma Completes Tender Offer for CollaGenex
7. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
8. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
9. AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair
10. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for SynOss(TM) Synthetic Mineral Bone Graft Material
11. Move Over, Popular Beauty Fillers--Here Comes Evolence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set ... one video to the next without having to set a single keyframe in ... to enhance your video production. , TransDark features dynamic transitions that momentarily splits the ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... An April 24th article on ... stunning 180 pounds with the help of a weight loss surgery. The woman, declaring “I ... skin that have been left following her dramatic weight loss. Dr. Feiz & Associates notes ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Beginning in 2017, ... their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure that ... the formula in the following ways:, , Removal of the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology: